When was Panacea Diagnostics founded?

Panacea Diagnostics was founded in 2023.

Where is Panacea Diagnostics located?

Panacea Diagnostics is headquartered in London, United Kingdom.

Where does Panacea Diagnostics rank among its competitors?

Panacea Diagnostics ranks 20th amongst 17 active competitors, of which 6 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Haga Bio Science, which secured $2.3M in Jun, 2026.

Who are the top competitors of Panacea Diagnostics?

Panacea Diagnostics' top competitors include Araceli Biosciences, ACD and Lodestone Biomedical. Among them, Haga Bio Science secured the most recent funding round in June, 2026.

Panacea Diagnostics - 2026 Company Profile, Funding & Competitors

Panacea Diagnostics is a funded company based in London (United Kingdom), founded in 2023. It operates as a Developer of diagnostic platforms for multiplexing assays in biological samples. The company has 17 active competitors, including 6 funded and 1 that has exited. Its top competitors include companies like Araceli Biosciences, ACD and Lodestone Biomedical.

Company Details

Developer of diagnostic platforms for multiplexing assays in biological samples. This technology utilizes photon tunneling to detect biomarkers across various matrices including serum, saliva, and capillary blood. The system supports applications ranging from research and drug development to clinical diagnostics. Laboratory services include porting specific assays onto the platform to achieve calibrated detection. The hardware is designed for use in clinical settings, pharmacies, and research environments.

Website: panaceadiagnostics.co.uk
Email ID: *****@panaceadiagnostics.co.uk

Key Metrics

Founded Year

2023

Location

London, United Kingdom

Stage

Funding Raised

Investors

Hoxton Ventures

Ranked

20^th among 20 competitors

Similar Companies

Araceli Biosciences & 18 more

View Panacea Diagnostics' full profile

Panacea Diagnostics is a funded company. Panacea Diagnostics has 1 institutional investor.

View details of Panacea Diagnostics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Panacea Diagnostics include Araceli Biosciences, ACD and Lodestone Biomedical. Here is the list of Top 10 competitors of Panacea Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Araceli Biosciences 2020, United States, Seed	Developer of scientific tools for tissue and cell-based biomarker discovery & drug development	$25.7M	-	53/100
2nd	ACD 2006, Newark (United States), Acquired	Developer of a transnational research platform for biomarker analysis	$39.4M	Summit Partners, Morningside & 5 others	52/100
3rd	Lodestone Biomedical 2015, Hanover (United States), Seed	Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology	$1.18M	MassChallenge, Dartmouth Regional Technology Center ... Read more	41/100
4th	BioAmp Diagnostics 2017, Berkeley (United States), Seed	Developers of diagnostic tests that help to treat patient with a specific antibiotic	-	Illumina, CITRIS Foundry & 8 others	35/100
5th	BioImage 1999, Copenhagen (Denmark), Acqui-Hired	Developer of bioassays for biopharmaceutical companies and research institutions	$30.5M	Abingworth, Novo Holdings & 3 others	32/100
6th	HAWK Biosystems 2015, Derio (Spain), Seed	Developer of clinical assays for quantifying novel biomarkers	-	EIC Fund, Europa	30/100
7th	Haga Bio Science Solna (Sweden), Seed	Developer of spatial RNA detection assays for clinical biomarker validation	$2.3M	Almi Invest, Life Science Invest	27/100
8th	Fyr Missoula (United States), Unfunded	Provider of extracellular vesicle omics platform for precision medicine advancement	-	-	25/100
9th	ACS Biomarker 2007, Maastricht (Netherlands), Series A	ACS Biomarker is a Dutch biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers for cardiac disease.	-	Brightlands Venture Partners, Life Sciences Fund Amsterdam ... & 3 others	24/100
10th	Cellkey 2019, Cheongju (South Korea), Unfunded	Provider of AI-driven multiomics data analysis and biomarker discovery solutions	-	-	24/100
20th	Panacea Diagnostics 2023, London (United Kingdom), Funding Raised	Developer of diagnostic platforms for multiplexing assays in biological samples	-	Hoxton Ventures	15/100